HLA-C and glioma: Whereas CAR T cells target predominantly tumor-associated cell surface antigens, TCR-engineered T cell therapy will strictly depend on intratumoral MHC class I or class II expression and antigen presentation by glioma cells and associated professional antigen-presenting cells, respectively (Figure 1).